Financials
- Fiscal year
- 2025
- Total assets
- €262,929
- Loss
- -€591,098
- Solvency
- -148.7%
Flindr Labs
ActiveSummary
The computed 12-month bankruptcy probability of Flindr Labs is 3.5% (moderate). The 2025 annual accounts show negative equity (-€391,098) and a net result of -€591,098. Its solvency ranks better than 6% of 58 sector peers (fiscal year 2025). The company has been active since 2024 and the Belgian State Gazette contains no insolvency or warning signals.
Overview
Activity
Manufacture of basic pharmaceutical products and pharmaceutical preparations
NACE 21201Research and development on biotechnology NACE 72101
1 site
Size
€262,929total assets 2025
- Staff
- 4.2 FTE
- Equity
- -€391,098
- Loss
- -€591,098
Turnover not published (abridged schema)
Structure
Accounts 38 d early1 of 2 deeds read
Why 47- Negative equity -€391,098- Loss of €591,098 (FY 2025)- Size: 4.2 FTE, total assets €262,929+ Sector Manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21)Show the evidence
Checked score
Score 2025
47
/ 100
Fair
Probability in this band: 1.5% to 4.2%
Better than 14% of its sector peers (NACE 21, micro)
Performance against the sector, not lower risk
Financial strength
Weak
Solvency
0
equity -148.7% of total assets
Liquidity
19
short-term debt 225.6% · cash 14.9%
Profitability
0
return on assets -224.8%
Bankruptcy probability, 12 months
3.5%
Moderate
0%0.5%1.5%4%10%≥ 25%
About 3 in 100 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
10-2025: 1.2%lowest value
11-2025: 1.2%● 0.0% vs 10-2025lowest value
12-2025: 1.3%▲ +4.0% vs 11-2025
01-2026: 1.4%▲ +7.6% vs 12-2025
02-2026: 1.5%▲ +5.7% vs 01-2026
03-2026: 1.7%▲ +11.8% vs 02-2026
04-2026: 1.7%● 0.0% vs 03-2026
05-2026: 1.8%▲ +10.3% vs 04-2026
06-2026: 1.9%▲ +2.0% vs 05-2026
07-2026: 3.3%▲ +77.9% vs 06-2026
08-2026: 3.3%● 0.0% vs 07-2026
09-2026: 3.4%▲ +4.3% vs 08-2026
10-2026: 3.5%▲ +0.5% vs 09-2026highest value
- Negative equity -€391,098 raises the probability
- Loss of €591,098 (FY 2025) raises the probability
- Size: 4.2 FTE, total assets €262,929 raises the probability for this profile
- Sector Manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21) lowers the probability
No credit on open account
Liquidity short (current ratio 0.25; short-term debt: 225.6% and cash: 14.9% of total assets), and equity is negative.
How it is calculated
The band comes from the bankruptcy probability on a scale of 0 to 100: every 10 points more double the odds of getting through the year without bankruptcy.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Place inside the band: half the bankruptcy probability, half how the company does against its sector peers (NACE 21, micro). Better than this share of them on solvency 10%, liquidity 19%, profitability 12%. That is performance, not lower risk; the band itself always comes from the probability.
Bankruptcy probability: model pd-v3.202610021621, computed on 04-10-2026. The model learns from Belgian bankruptcies and reads the registers, the annual accounts and the gazette.
Ceilings: negative or zero equity, a heavy loss, a special KBO legal situation and a missing filing 59 (two missing 44), an ongoing judicial reorganisation or an ending 24. Financial strength does not count in the score.
Credit check for your own amount and term
Show the recommended maximum : and see how the verdict changes with amount, term and advance.
Signals
Seven signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Young company
Founded in 2024, under 3 years in business. Failure risk is statistically highest between 2 and 8 years after founding.
KBO · incorporation dateAge against the risk zone
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 23-06-2026, 38 days ahead of the deadline.
NBB · 1 filingDeviation from the deadline
2025
38 d early
← before the deadline
after the deadline →
Checked, nothing found (1)
- MiscellaneousCapital contribution · Power of…
- Annual accounts filedfiscal year 2025 · abbreviated…
Key points
By topic
Timeline
- Events
- 2
- Since
- 2026
- 25-06-2026Miscellaneous
- 23-06-2026Annual accounts filed
Company details
- Sites
- 1
- Legal form
- Private limited company
- Activity
- Manufacture of basic pharmaceutical products and pharmaceutical preparationsNACE 21201
- Founded
- 25-09-2024
- Year ends
- 31-12
- Peppol
- Reachable for e-invoices
Go further with this company
How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check What other support did companies like this one receive, and it did not?Subsidies How does this company compare with its sector?Sector benchmark
Your own company? See how customers, suppliers and banks see it and what to improve first.
Investigating this company? Keep it with today's facts in a case file.